A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris
In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind t...
Gespeichert in:
| Veröffentlicht in: | Acta dermato-venereologica 2002, Vol.82 (2), p.131-135 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 2 |
| container_start_page | 131 |
| container_title | Acta dermato-venereologica |
| container_volume | 82 |
| creator | DOUGLAS, W. S POULIN, Y BIBBY, A. J DECROIX, J ORTONNE, J. P MROWIETZ, U GULLIVER, W KROGSTAD, A. L LARSEN, F. G IGLESIAS, L BUCKLEY, C |
| description | In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p |
| doi_str_mv | 10.1080/00015550252948194 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_00015550252948194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12125943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2854-3204d85d7193b44a4a0adc5abd350a255b605210f8bbd8cf9d31a0a4b437c4ba3</originalsourceid><addsrcrecordid>eNplkMtKAzEUhrNQbK0-gBvJxmVtrp2ZZSneoOBG1-XkMjYyMxmS1NJH8i1NmUIVVyEn3_dz8iN0Q8k9JSWZEUKolJIwySpR0kqcofFhNs1DOUKXMX7mK5O0vEAjyiiTleBj9L3And1hDY12vU_B-WambILWpg1E31lc-9BuG0jOd3jn0gYH6J3Bvos2YV9j0MMTRBy3vc0JASePW9_5tLEZ3g_a31Tj-uD7LEKyOBu_F8Cuw330wUF0EX9tmw8ILl6h8xqaaK-P5wS9Pz68LZ-nq9enl-ViNdWslGLKGRGmlKagFVdCgAACRktQhksCTEo1J5JRUpdKmVLXleE0I0IJXmihgE8QHXJ18DEGW6_74FoI-zUl60PV639VZ-d2cPqtaq05GceeM3B3BCDmr9YBOu3iieOFpEU55z_NWY3M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DOUGLAS, W. S ; POULIN, Y ; BIBBY, A. J ; DECROIX, J ; ORTONNE, J. P ; MROWIETZ, U ; GULLIVER, W ; KROGSTAD, A. L ; LARSEN, F. G ; IGLESIAS, L ; BUCKLEY, C</creator><creatorcontrib>DOUGLAS, W. S ; POULIN, Y ; BIBBY, A. J ; DECROIX, J ; ORTONNE, J. P ; MROWIETZ, U ; GULLIVER, W ; KROGSTAD, A. L ; LARSEN, F. G ; IGLESIAS, L ; BUCKLEY, C</creatorcontrib><description>In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p <0.001). The differences in PASI were also statistically significant after 1 week. In the double-blind phase, 8.1% of patients (combination) reported lesional/ perilesional adverse reactions compared to 4.7% (betamethasone) and 12.0% (calcipotriol). In the combination group, mean PASI at the end of the double-blind phase was 2.5, and at end of the unblinded phase 3.6, compared with 3.9 and 4.1 (betamethasone) and 4.4 and 3.7 (calcipotriol). Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated. It is safe to transfer patients from combination to calcipotriol, with maintenance of clinical effect.</description><identifier>ISSN: 0001-5555</identifier><identifier>DOI: 10.1080/00015550252948194</identifier><identifier>PMID: 12125943</identifier><identifier>CODEN: ADVEA4</identifier><language>eng</language><publisher>Uppsala: Acta dermato-venereologica</publisher><subject><![CDATA[Administration, Topical ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - adverse effects ; Betamethasone - administration & dosage ; Betamethasone - adverse effects ; Betamethasone - analogs & derivatives ; Biological and medical sciences ; Calcitriol - administration & dosage ; Calcitriol - adverse effects ; Calcitriol - analogs & derivatives ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - adverse effects ; Double-Blind Method ; Drug Combinations ; Female ; Glucocorticoids ; Humans ; Male ; Medical sciences ; Middle Aged ; Ointments ; Pharmacology. Drug treatments ; Psoriasis - drug therapy ; Skin, nail, hair, dermoskeleton]]></subject><ispartof>Acta dermato-venereologica, 2002, Vol.82 (2), p.131-135</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2854-3204d85d7193b44a4a0adc5abd350a255b605210f8bbd8cf9d31a0a4b437c4ba3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13751786$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12125943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DOUGLAS, W. S</creatorcontrib><creatorcontrib>POULIN, Y</creatorcontrib><creatorcontrib>BIBBY, A. J</creatorcontrib><creatorcontrib>DECROIX, J</creatorcontrib><creatorcontrib>ORTONNE, J. P</creatorcontrib><creatorcontrib>MROWIETZ, U</creatorcontrib><creatorcontrib>GULLIVER, W</creatorcontrib><creatorcontrib>KROGSTAD, A. L</creatorcontrib><creatorcontrib>LARSEN, F. G</creatorcontrib><creatorcontrib>IGLESIAS, L</creatorcontrib><creatorcontrib>BUCKLEY, C</creatorcontrib><title>A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris</title><title>Acta dermato-venereologica</title><addtitle>Acta Derm Venereol</addtitle><description>In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p <0.001). The differences in PASI were also statistically significant after 1 week. In the double-blind phase, 8.1% of patients (combination) reported lesional/ perilesional adverse reactions compared to 4.7% (betamethasone) and 12.0% (calcipotriol). In the combination group, mean PASI at the end of the double-blind phase was 2.5, and at end of the unblinded phase 3.6, compared with 3.9 and 4.1 (betamethasone) and 4.4 and 3.7 (calcipotriol). Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated. It is safe to transfer patients from combination to calcipotriol, with maintenance of clinical effect.</description><subject>Administration, Topical</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Betamethasone - administration & dosage</subject><subject>Betamethasone - adverse effects</subject><subject>Betamethasone - analogs & derivatives</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - administration & dosage</subject><subject>Calcitriol - adverse effects</subject><subject>Calcitriol - analogs & derivatives</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Double-Blind Method</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ointments</subject><subject>Pharmacology. Drug treatments</subject><subject>Psoriasis - drug therapy</subject><subject>Skin, nail, hair, dermoskeleton</subject><issn>0001-5555</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkMtKAzEUhrNQbK0-gBvJxmVtrp2ZZSneoOBG1-XkMjYyMxmS1NJH8i1NmUIVVyEn3_dz8iN0Q8k9JSWZEUKolJIwySpR0kqcofFhNs1DOUKXMX7mK5O0vEAjyiiTleBj9L3And1hDY12vU_B-WambILWpg1E31lc-9BuG0jOd3jn0gYH6J3Bvos2YV9j0MMTRBy3vc0JASePW9_5tLEZ3g_a31Tj-uD7LEKyOBu_F8Cuw330wUF0EX9tmw8ILl6h8xqaaK-P5wS9Pz68LZ-nq9enl-ViNdWslGLKGRGmlKagFVdCgAACRktQhksCTEo1J5JRUpdKmVLXleE0I0IJXmihgE8QHXJ18DEGW6_74FoI-zUl60PV639VZ-d2cPqtaq05GceeM3B3BCDmr9YBOu3iieOFpEU55z_NWY3M</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>DOUGLAS, W. S</creator><creator>POULIN, Y</creator><creator>BIBBY, A. J</creator><creator>DECROIX, J</creator><creator>ORTONNE, J. P</creator><creator>MROWIETZ, U</creator><creator>GULLIVER, W</creator><creator>KROGSTAD, A. L</creator><creator>LARSEN, F. G</creator><creator>IGLESIAS, L</creator><creator>BUCKLEY, C</creator><general>Acta dermato-venereologica</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2002</creationdate><title>A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris</title><author>DOUGLAS, W. S ; POULIN, Y ; BIBBY, A. J ; DECROIX, J ; ORTONNE, J. P ; MROWIETZ, U ; GULLIVER, W ; KROGSTAD, A. L ; LARSEN, F. G ; IGLESIAS, L ; BUCKLEY, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2854-3204d85d7193b44a4a0adc5abd350a255b605210f8bbd8cf9d31a0a4b437c4ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Administration, Topical</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Betamethasone - administration & dosage</topic><topic>Betamethasone - adverse effects</topic><topic>Betamethasone - analogs & derivatives</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - administration & dosage</topic><topic>Calcitriol - adverse effects</topic><topic>Calcitriol - analogs & derivatives</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Double-Blind Method</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ointments</topic><topic>Pharmacology. Drug treatments</topic><topic>Psoriasis - drug therapy</topic><topic>Skin, nail, hair, dermoskeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOUGLAS, W. S</creatorcontrib><creatorcontrib>POULIN, Y</creatorcontrib><creatorcontrib>BIBBY, A. J</creatorcontrib><creatorcontrib>DECROIX, J</creatorcontrib><creatorcontrib>ORTONNE, J. P</creatorcontrib><creatorcontrib>MROWIETZ, U</creatorcontrib><creatorcontrib>GULLIVER, W</creatorcontrib><creatorcontrib>KROGSTAD, A. L</creatorcontrib><creatorcontrib>LARSEN, F. G</creatorcontrib><creatorcontrib>IGLESIAS, L</creatorcontrib><creatorcontrib>BUCKLEY, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta dermato-venereologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOUGLAS, W. S</au><au>POULIN, Y</au><au>BIBBY, A. J</au><au>DECROIX, J</au><au>ORTONNE, J. P</au><au>MROWIETZ, U</au><au>GULLIVER, W</au><au>KROGSTAD, A. L</au><au>LARSEN, F. G</au><au>IGLESIAS, L</au><au>BUCKLEY, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris</atitle><jtitle>Acta dermato-venereologica</jtitle><addtitle>Acta Derm Venereol</addtitle><date>2002</date><risdate>2002</risdate><volume>82</volume><issue>2</issue><spage>131</spage><epage>135</epage><pages>131-135</pages><issn>0001-5555</issn><coden>ADVEA4</coden><abstract>In this study, we compared a new combination ointment containing both calcipotriol and betamethasone dipropionate with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) in patients with psoriasis vulgaris; 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage change in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group) and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p < 0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p <0.001). The differences in PASI were also statistically significant after 1 week. In the double-blind phase, 8.1% of patients (combination) reported lesional/ perilesional adverse reactions compared to 4.7% (betamethasone) and 12.0% (calcipotriol). In the combination group, mean PASI at the end of the double-blind phase was 2.5, and at end of the unblinded phase 3.6, compared with 3.9 and 4.1 (betamethasone) and 4.4 and 3.7 (calcipotriol). Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated. It is safe to transfer patients from combination to calcipotriol, with maintenance of clinical effect.</abstract><cop>Uppsala</cop><pub>Acta dermato-venereologica</pub><pmid>12125943</pmid><doi>10.1080/00015550252948194</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-5555 |
| ispartof | Acta dermato-venereologica, 2002, Vol.82 (2), p.131-135 |
| issn | 0001-5555 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_00015550252948194 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Administration, Topical Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Betamethasone - administration & dosage Betamethasone - adverse effects Betamethasone - analogs & derivatives Biological and medical sciences Calcitriol - administration & dosage Calcitriol - adverse effects Calcitriol - analogs & derivatives Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Double-Blind Method Drug Combinations Female Glucocorticoids Humans Male Medical sciences Middle Aged Ointments Pharmacology. Drug treatments Psoriasis - drug therapy Skin, nail, hair, dermoskeleton |
| title | A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A19%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20calcipotriol/betamethasone%20formulation%20with%20rapid%20onset%20of%20action%20was%20superior%20to%20monotherapy%20with%20betamethasone%20dipropionate%20or%20calcipotriol%20in%20psoriasis%20vulgaris&rft.jtitle=Acta%20dermato-venereologica&rft.au=DOUGLAS,%20W.%20S&rft.date=2002&rft.volume=82&rft.issue=2&rft.spage=131&rft.epage=135&rft.pages=131-135&rft.issn=0001-5555&rft.coden=ADVEA4&rft_id=info:doi/10.1080/00015550252948194&rft_dat=%3Cpubmed_cross%3E12125943%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12125943&rfr_iscdi=true |